ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2020 Operating Results
ImmunoGen, a leader in antibody-drug conjugates for cancer treatment, will host a conference call on November 6, 2020, at 8:00 a.m. ET to discuss its third-quarter operating results. The call will include a business update and can be accessed by phone at (877) 621-5803 with conference ID 9864218. Investors can also listen through the company’s website. ImmunoGen focuses on developing next-generation therapies to improve cancer patient outcomes, committing to 'target a better now.'
- Scheduled conference call to discuss third-quarter results, indicating transparency.
- Focus on developing next-generation antibody-drug conjugates to improve patient outcomes.
- None.
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 6, 2020 to discuss its third quarter operating results. Management will also provide a brief update on the business.
Conference Call Information
To access the live call by phone, dial (877) 621-5803; the conference ID is 9864218. The call may also be accessed through the Investors and Media section of the Company’s website, www.immunogen.com. Following the call, a replay will be available at the same location.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.”
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
